Books and Book Chapters

    Systems Toxicology

    Talikka, M.; Boue, S.; Frentzel, S.; Kogel, U.; Sierro, N.; Titz, B.; Veljkovic, E.; Hoeng, J.; Peitsch, M. C.

    Date published
    Jun 15, 2016
    DOI
    10.1002/9780470921920.edm143
    ISBN
    9780470921920
    Published in
    Encyclopedia of Drug Metabolism and Interactions
    Editors
    Lyubimov, A. V.
    Link to publication
    Topic
    Summary

    The human respiratory tract is exposed to numerous contaminants; traditional toxicity testing methods are insufficient to understand the extent of their biological impact and to recommend dose guidelines for safe exposure. Systems toxicology approaches are starting to shape the way for a better assessment of toxicity associated with inhaled substances. A well-designed assessment pipeline begins with the choice of the experimental system, exposure modality, and characterization of the exposure. The different omics technologies are a crucial part of modern toxicity testing by providing a holistic, unbiased view of a substance's impact. Transcriptomics technologies give insight into the differential expression of genes resulting from exposures, and genomics technologies assess the impact on the DNA itself. Large-scale proteomics and metabolomics measurements provide additional layers of data and enable the detailed interpretation of the outcome of differential gene expression and the analysis of processes. Network biology is emerging as a powerful tool to filter relevant signal from noise using a priori knowledge. The quantitative aspect of network scoring allows the comparison of different doses and exposure durations and represents the impact as a single holistic score. Crowd sourcing facilitates the collaborative and transparent establishment and verification of toxicity testing methods.

    Related Publications

    A comparative assessment of HPHC yields and in vitro toxicity for 1R6F reference cigarette smoke versus aerosol generated by Tobacco Heating System 3.0

    Pre-clinical Toxicology

    Cigarette smoke enhances abdominal aortic aneurysm formation in angiotensin II-treated apolipoprotein E-deficient mice

    Pre-clinical Toxicology

    Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

    Pre-clinical Toxicology

    Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

    Pre-clinical Toxicology

    Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

    Pre-clinical Toxicology

    Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

    Pre-clinical Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.